Intervention debulking surgery in advanced epithelial ovarian cancer

Objective To study whether intervention debulking surgery improves survival in patients with advanced ovarian cancer who have bulky (> 2 cm) residual disease after primary surgery.

[1]  C. Redman,et al.  Early second surgery in ovarian cancer--improving the potential for cure or another unnecessary operation? , 1990, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[2]  C. Redman,et al.  Neoadjuvant (Cytoreductive) Chemotherapy Combined With Intervention Debulking Surgery in Advanced, Unresected Epithelial Ovarian Cancer , 1989, Obstetrics and gynecology.

[3]  G. Blackledge,et al.  FAILURE OF SECOND-LOOK LAPAROTOMY TO INFLUENCE SURVIVAL IN EPITHELIAL OVARIAN CANCER , 1988, The Lancet.

[4]  P. Schwartz,et al.  Evaluation of the role of second‐look surgery in ovarian cancer , 1988, Obstetrics and gynecology.

[5]  N. Colombo,et al.  A reassessment of the role of second-look laparotomy in advanced ovarian cancer. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  G. Blackledge,et al.  Speed of response to platinum-based chemotherapy: implications for the management of epithelial ovarian cancer. , 1987, European journal of cancer & clinical oncology.

[7]  A. Heintz,et al.  Cytoreductive surgery in ovarian carcinoma: Feasibility and morbidity , 1986 .

[8]  M. Piver,et al.  The potential for optimal (⩽ 2 cm) cytoreductive surgery in advanced ovarian carcinoma at a tertiary medical center: A prospective study , 1986 .

[9]  R. Elashoff,et al.  Survival of Patients Following Secondary Cytoreductive Surgery in Ovarian Cancer , 1983, Obstetrics and gynecology.

[10]  C. Griffiths,et al.  Role of cytoreductive surgical treatment in the management of advanced ovarian cancer. , 1979, Cancer treatment reports.

[11]  J H Goldie,et al.  A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. , 1979, Cancer treatment reports.